Advertisement

Acute Lymphoblastic Leukemia in Young Adults Treated with Intensive “Pediatric” Type Protocol

  • Prasanth Ganesan
  • Tenali Gnana Sagar
  • Krishnarathinam Kannan
  • Venkatraman Radhakrishnan
  • Manikandan Dhanushkodi
  • Rajaraman Swaminathan
  • Shirley Sundersingh
  • Trivadi S. Ganesan
Original Article
  • 76 Downloads

Abstract

Young adults with acute lymphoblastic leukemia do better when treated on “pediatric” protocols. Young adults (18–30 years) with Ph-negative ALL treated between 2000 and 2014 were retrospectively analyzed. Two-hundred and thirty-two patients were included [median age 21 years (18–30); 176 (76%) males; median WBC 16,000/cmm]. Protocols used were: BFM 95 (N = 147, 63%), MCP-841 (N = 51, 22%), GMALL (N = 21, 9%), INCTR (N = 9, 4%) and UKALL (N = 4, 2%). Complete remission was achieved in 194/232 (84%). Twenty patients (9%) died due to toxicity which was higher with BFM versus others (18/147 vs. 2/85; p = 0.031). After a median follow-up of 48 months, median RFS and OS were 35.5 months (25–46), and 25 months (18–31) and actuarial RFS and OS (5-years) were 45% (37–53) and 39% (32–46). BFM protocol improved RFS (51 vs. 35%, p = 0.027) but not OS (43 vs. 33%, p = 0.2). The survival outcomes reported are 15–20% lower than those reported from West. Better supportive care and risk-adapted therapy may improve outcomes.

Keywords

Acute lymphoblastic leukemia India BFM protocol Young adult 

Notes

Acknowledgement

Ms. Vanitha Rajagopalan for helping with collection of data. We acknowledge financial support from Rashtriya Arogya Nidhi, Indian Cancer Society Fund, and the Kalyani Memorial Fund for provided support which partly offset the treatment costs of these patients.

Funding

The study was supported by Cancer Institute (WIA) funds. No Grant number is applicable.

Compliance with Ethical Standards

Conflict of interest

None of the authors have any relevant conflicts of interests to declare.

Ethical Approval

This study was a retrospective analysis of outcomes and doesn’t require ethical committee approval as per our Institute policy.

Supplementary material

12288_2017_892_MOESM1_ESM.docx (41 kb)
Supplementary material 1 (DOCX 41 kb)

References

  1. 1.
    Curran E, Stock W (2015) How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood 125(24):3702–3710CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Dhédin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V et al (2015) Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood 125(16):2486–2496 quiz 586 CrossRefPubMedGoogle Scholar
  3. 3.
    Radhakrishnan V, Gupta S, Ganesan P, Rajendranath R, Ganesan TS, Rajalekshmy KR et al (2015) Acute lymphoblastic leukemia: a single center experience with Berlin, Frankfurt, and Munster-95 protocol. Indian J Med Paediatr Oncol 36(4):261–264CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Gökbuget N, Hoelzer D, Arnold R, Böhme A, Bartram CR, Freund M et al (2000) Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 14(6):1307–1325, ixCrossRefPubMedGoogle Scholar
  5. 5.
    Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM et al (2005) Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 106(12):3760–3767CrossRefPubMedGoogle Scholar
  6. 6.
    Arya LS, Kotikanyadanam SP, Bhargava M, Saxena R, Sazawal S, Bakhshi S et al (2010) Pattern of relapse in childhood ALL: challenges and lessons from a uniform treatment protocol. J Pediatr Hematol Oncol 32(5):370–375CrossRefPubMedGoogle Scholar
  7. 7.
    Mukhopadhyay D, Gupta P, Mukhopadhyay S, Chitalkar P, Banavali SD, Advani SH et al (2007) Result of childhood acute lymphoblastic leukemia protocol (INCTR) from a developing country[abstract]. J Clin Oncol 25(18S):20015Google Scholar
  8. 8.
    Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M et al (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111(9):4477–4489CrossRefPubMedGoogle Scholar
  9. 9.
    Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA et al (2015) Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol 170(1):110–117CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hough R, Rowntree C, Goulden N, Mitchell C, Moorman A, Wade R et al (2016) Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003. Br J Haematol 172(3):439–451CrossRefPubMedGoogle Scholar
  11. 11.
    Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R et al (2013) Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 14(3):199–209CrossRefPubMedGoogle Scholar
  12. 12.
    Ribera JM, Oriol A, Sanz MA, Tormo M, Fernández-Abellán P, del Potro E et al (2008) Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. J Clin Oncol 26(11):1843–1849CrossRefPubMedGoogle Scholar
  13. 13.
    Usvasalo A, Räty R, Knuutila S, Vettenranta K, Harila-Saari A, Jantunen E et al (2008) Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica 93(8):1161–1168CrossRefPubMedGoogle Scholar
  14. 14.
    Rijneveld AW, van der Holt B, Daenen SM, Biemond BJ, de Weerdt O, Muus P et al (2011) Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia 25(11):1697–1703CrossRefPubMedGoogle Scholar
  15. 15.
    DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG et al (2015) Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 29(3):526–534CrossRefPubMedGoogle Scholar
  16. 16.
    Beck J, Brandt K, Bruggemann M, Burmeister T, Diedrich H, Faul C et al (2013) Significant improvement of outcome in adolescents and young adults (AYAs) aged 15–35 years with acute lymphoblastic leukemia (ALL) with a pediatric derived adult ALL protocol; results of 1529 AYAs in 2 consecutive trials of the German Multicenter Study Group for Adult ALL (GMALL). Blood 122(21):389Google Scholar
  17. 17.
    Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O et al (2014) Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J 4:e252CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Stock W, Luger SM, Advani AS, Geyer S, Harvey RC, Mullighan CC et al (2014) Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of U.S. Intergroup Trial C10403. Blood 124(21):796Google Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2017

Authors and Affiliations

  • Prasanth Ganesan
    • 1
  • Tenali Gnana Sagar
    • 1
  • Krishnarathinam Kannan
    • 1
  • Venkatraman Radhakrishnan
    • 1
  • Manikandan Dhanushkodi
    • 1
  • Rajaraman Swaminathan
    • 3
  • Shirley Sundersingh
    • 2
  • Trivadi S. Ganesan
    • 1
  1. 1.Department of Medical OncologyCancer Institute (WIA)ChennaiIndia
  2. 2.Department of PathologyCancer Institute (WIA)ChennaiIndia
  3. 3.Department of Biostatistics and Tumor RegistryCancer Institute (WIA)ChennaiIndia

Personalised recommendations